Hand-foot syndrome (HFS) is a common dose-limiting toxicity of capecitabine that impairs quality of life and can lead to treatment modification or discontinuation. Predictive markers for HFS remain unclear. This study aimed to identify clinical and biochemical factors associated with the development and severity of HFS in patients receiving capecitabine.
Methods
We conducted a retrospective cohort study of patients with breast, colorectal, or gastric cancer who received capecitabine between December 2017 and December 2019. Patients were eligible if they received at least one treatment cycle and had follow-up data for 12 weeks. HFS incidence and severity were assessed using CTCAE version 4.0. Associations between clinical factors and HFS were evaluated using univariate analysis and time-dependent Cox proportional hazards models.
Results
Among 146 patients, 55 (37.7%) developed HFS: Grade 1 (n = 28), Grade 2 (n = 21), and Grade 3 (n = 6). No patients discontinued treatment due to HFS. In the prespecified model, cumulative capecitabine dose was not significantly associated with HFS. However, in exploratory analysis, increased alanine aminotransferase (ALT) levels were associated with both the development (HR: 1.02; 95% CI: 1.00–1.04; p = 0.02) and severity (HR: 1.03; 95% CI: 1.01–1.05; p = 0.01) of HFS.
Conclusions
Increased ALT may serve as a potential biomarker for predicting HFS risk in capecitabine-treated patients. This finding could aid in early identification and management of at-risk patients, improving treatment outcomes.
Chavarri-GuerraYSoto-Perez-de-CelisE. Loss of fingerprints. N Engl J Med2015; 372: 22.
2.
ChoiJN. Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts. Clin Dermatol2011; 29: 587–601.
3.
Al-AhwalMS. Chemotherapy and fingerprint loss: beyond cosmetic. Oncologist2012; 17: 291–293.
4.
GrotheyAGeorgeSvan CutsemE, et al.Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist2014; 19: 669–680.
5.
WuZZhangXZhangC, et al.Meta-analysis of capecitabine versus 5-fluorouracil in advanced gastric cancer. Evid Based Complement Alternat Med2023; 2023: 4946642.
6.
KwakmanJJMElshotYSPuntCJA, et al.Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev2020; 14: 442.
7.
MillerKKGorceyLMcLellanBN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol2014; 71: 787–794.
8.
ŞavlıE. Capecitabine-induced hand-foot syndrome: a brief look at possible pathways that may be associated with inflammation. ODU Tip Derg2024; 11: 55–67.
9.
PayneASJamesWDWeissRB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol2006; 33: 86–97.
10.
WolfSLQinRMenonSP, et al.Placebo-controlled trial to determine the effectiveness of a urea/lactic acid–based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol2010; 28: 5182–5187.
11.
HofheinzRDGencerDSchulzH, et al.Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO Quality of Life Working Group. J Clin Oncol2015; 33: 2444–2449.
12.
YokomichiNNagasawaTColer-ReillyA, et al.Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. Hum Cell2013; 26: 8–18.
13.
ZhangRXWuXJWanDS, et al.Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol2012; 23: 1348–1353.
14.
NissenSEYeomansNDSolomonDH, et al.Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med2016; 375: 2519–2529.
15.
PandyJGPFrancoPIGLiRK. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer2022; 30: 8655–8666.
16.
GalloisCShiQMeyersJP, et al.Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 adjuvant trials. J Clin Oncol2023; 41: 803–815.
HofheinzRDHeinemannVvon WeikersthalLF, et al.Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer2012; 107: 1678–1683.
19.
KangYKLeeSSYoonDH, et al.Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol2010; 28: 3824–3829.
20.
Du BoisDDu BoisEF. A formula to estimate the approximate surface area if height and weight be known. Nutrition1989; 5: 303–312.
21.
NaitoMYamamotoTHaraS, et al.Hemoglobin value is the most important factor in the development of hand-foot syndrome under the capecitabine regimen. Chemotherapy2017; 62: 23–29.
22.
KandaY. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant2013; 48: 452–458.
23.
YokokawaTKawakamiKMaeY, et al.Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy. Ann Pharmacother2015; 49: 1120–1124.
AritaHUedaSKoyamaY, et al.Usefulness of tracing reports based on CTCAE for outpatient cancer chemotherapy. Jpn J Pharm Health Care Sci2021; 47: 649–658.
26.
ChuMPHechtJRSlamonD, et al.Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol2017; 3: 767–773.
27.
SekidoMFujitaKKubotaY, et al.Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil. Cancer Chemother Pharmacol2019; 83: 1127–1135.
28.
YapYSKwokLLSynN, et al.Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine–induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol2017; 3: 1538–1545.
29.
van KuilenburgAB. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest2006; 24: 215–217.
30.
YenJLMcLeodHL. Should DPD analysis be required prior to prescribing fluoropyrimidines?Eur J Cancer2007; 43: 1011–1016.
31.
ReizineNMDanaheyKTruongTM, et al.Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer2022; 128: 1649–1657.
32.
RosmarinDPallesCChurchD, et al.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol2014; 32: 1031–1039.
33.
LouYWangQZhengJ, et al.Identification of the novel capecitabine metabolites in capecitabine-treated patients with hand-foot syndrome. Chem Res Toxicol2018; 31: 1069–1079.
